Andrew D. Goldberg, MD

Andrew D. Goldberg, MD, was appointed Chief Executive Officer of AchieveRx in April 2026. Andrew is a physician, healthcare investor, and governance leader who has spent his career at the intersection of clinical medicine and commercial execution. Most recently, he served as a Portfolio Manager at Marshall Wace and previously as a Partner at Vivo Capital, a healthcare-focused investment firm. Earlier in his career, he was a consultant at McKinsey & Company in Silicon Valley, advising pharmaceutical, biotechnology, and medical device companies. He has served as a board director or observer at 19 life sciences companies, including Tarsus Pharmaceuticals (Nasdaq: TARS) through FDA approval and the national launch and commercialization of XDEMVY, Veradermics (NYSE: MANE) through its successful IPO, Inquis Medical through FDA approval and commercialization of the Aventus thrombectomy system, Elektrofi through its $900M acquisition by Halozyme Therapeutics (Nasdaq: HALO), Parse Biosciences through its acquisition by Qiagen (NYSE: QGEN), and Forge Biologics through its acquisition by Ajinomoto. As lead investor, he anchored the U.S. market transition for Verona Pharma (Nasdaq: VRNA), culminating in the $10.8B acquisition by Merck, and led the pre-IPO investment in Harmony Biosciences (Nasdaq: HRMY), which scaled WAKIX into a new category in sleep medicine. Dr. Goldberg is among the first physicians in the United States to earn dual board certification in Critical Care Medicine and Emergency Medicine. He served as an Instructor in Medicine at the Mayo Clinic, where he completed a Critical Care fellowship, after training in Emergency Medicine at LAC+USC. He has over 25 scientific publications including research on tobacco advertising, published in JAMA, that examined youth targeting and contributed to public-health initiatives that earned him the Oregon Governor’s Council Outstanding Achievement Award. Dr. Goldberg received his MD from The George Washington University School of Medicine and a post-doctoral diploma in translational science from the Mayo Graduate School.